AAPS workshop report: Strategies to address therapeutic protein-drug interactions during clinical development

AAPS Journal

Volumn 13, Issue 3, 2011, Pages 405-416

  Girish, Sandhya ^a   Martin, Steven W ^b   Peterson, Mark C ^b   Zhang, Lei K ^c   Zhao, Hong ^c   Balthasar, Joseph ^d   Evers, Raymond ^e   Zhou, Honghui ^f   Zhu, Min ^g   Klunk, Lewis ^h   Han, Chao ^f   Berglund, Eva Gil ⁱ   Huang, Shiew Mei ^c   Joshi, Amita ^a  

^a GENENTECH INC   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^d UNIVERSITY AT BUFFALO   (United States)

^e MERCK RESEARCH LABORATORIES   (United States)

^f Centocor RandD Johnson and Johnson   (United States)

^g AMGEN INC   (United States)

^h BIOGEN   (United States)

ⁱ MEDICAL PRODUCTS AGENCY   (Sweden)

Author keywords

drug interactions; question based; regulatory; risk based; therapeutic proteins

Indexed keywords

ADALIMUMAB; BASILIXIMAB; BEVACIZUMAB; CYCLOSPORIN A; DEXTROMETHORPHAN; EFALIZUMAB; ERLOTINIB; ETANERCEPT; HEPARIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; IRINOTECAN; METHOTREXATE; MONOCLONAL ANTIBODY; OKT 3; OMEPRAZOLE; PACLITAXEL; PALIFERMIN; PLACEBO; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RECOMBINANT INTERLEUKIN 11; RECOMBINANT INTERLEUKIN 2; RITUXIMAB; SIMVASTATIN; TACROLIMUS; TOCILIZUMAB; TRASTUZUMAB;

BIOTECHNOLOGY; CANCER THERAPY; CASE STUDY; CONFERENCE PAPER; CONJUNCTIVAL HEMORRHAGE; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DEVELOPMENT; DRUG INFORMATION; DRUG LABELING; DRUG MECHANISM; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; EDEMA; EUROPE; GOVERNMENT REGULATION; HUMAN; HYPOTENSION; IN VITRO STUDY; INFECTION; MOLECULAR SIZE; PRACTICE GUIDELINE; PROTEIN DRUG INTERACTION; PROTEIN INTERACTION; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SINGLE DRUG DOSE; STRATEGIC PLANNING; TACHYCARDIA; WORKSHOP;

CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; DRUG INDUSTRY; DRUG INTERACTIONS; HUMANS; PHARMACEUTICAL PREPARATIONS; PROTEINS;

EID: 80052604122     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-011-9285-6     Document Type: Conference Paper

References (42)

1. JI Lee L Zhang AY Men LA Kenna SM Huang 2010 CYP-medicated therapeutic protein-drug interactions clinical findings, proposed mechanisms and regulatory implications Clin Pharmacokinet 49 5 295 310 20384392 10.2165/11319980- 000000000-00000 1:CAS:528:DC%2BC3cXnslaqt7s%3D
2. S-M Huang H Zhao JI Lee K Reynolds L Zhang R Temple, et al. 2010 Therapeutic protein-drug interactions and implications for drug development Clin Pharmacol Ther 87 497 503 20200513 10.1038/clpt.2009.308 1:CAS:528: DC%2BC3cXjs1ajsbY%3D
3. K Seitz H Zhou 2007 Pharmacokinetic drug-drug interaction potentials for therapeutic monoclonal antibodies: reality check J Clin Pharmacol 47 1104 1118 17766698 10.1177/0091270007306958 1:CAS:528:DC%2BD2sXhtVKhurvK
4. H Zhou HM Davis 2009 Risk-based strategy for the assessment of pharmacokinetic drug-drug interactions for therapeutic monoclonal antibodies Drug Discov Today 14 17-18 891 898 19520183 10.1016/j.drudis.2009.05.014 1:CAS:528:DC%2BD1MXhtV2ksL3L
5. I Mahmood MD Green 2007 Drug interaction studies of therapeutic proteins or monoclonal antibodies J Clin Pharmacol 47 1540 1554 17962422 10.1177/0091270007308616 1:CAS:528:DC%2BD2sXhsVyjtr%2FK (Pubitemid 350115304)
6. ET Morgan 2009 Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics Clin Pharmacol Ther 85 4 434 438 19212314 10.1038/clpt.2008.302 1:CAS:528:DC%2BD1MXjtlSmurg%3D
7. US Food and Drug Administration. Draft Guidance for industry: drug interaction studies-study design, data analysis and implications for dosing and labelling. Rockville, MD. 2006. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm072101.pdf or FDA Drug Interaction and Drug Development website: http://www.fda.gov/Drugs/ DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ ucm080499.htm. Accessed 04 Jan 2010.
8. European Medicines Agency. Guideline on the clinical investigation of the pharmacokinetics of therapeutic proteins CHMP/EWP/89249/2004. London, UK. 2007. http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general- content-000370.jsp&murl=menus/regulations/regulations.jsp&mid= WC0b01ac0580032ec5. Accessed 15 Jan 2011.
9. GP Pageaux Y Le Bricquir F Berthou N Bressot M-C Picot F Blanc, et al. 1998 Effects of interferon-alpha on cytochrome P-450 isoforms 1A2 and 3A activities in patients with chronic hepatitis C Eur J Gastroenterol Hepatol 10 491 495 9855065 10.1097/00042737-199806000-00010 1:STN:280: DyaK1M%2FntVOjtQ%3D%3D (Pubitemid 28306542)
10. L Becquemont O Chazouilleres L Serfaty JM Poirier F Broly P Jailon, et al. 2002 Effect of interferon α-ribavirin bitherapy on cytochrome P450 1A2 and 2D6 and N-acetyltransferase-2 activities in patients with chronic hepatitis C Clin Pharmacol Ther 71 488 495 12087352 10.1067/mcp.2002.124468 1:CAS:528:DC%2BD38XlslCkt7s%3D (Pubitemid 34701356)
11. J Elkahwaji MA Robin A Berson M Tinel P Letteron G Labbe, et al. 1999 Decrease in hepatic cytochrome P450 after interleukine-2 immunotherapy Biochem Pharmacol 57 951 954 10086330 10.1016/S0006-2952(98)00372-4 1:CAS:528: DyaK1MXhvFSkt78%3D (Pubitemid 29127109)
12. JC Gorski SD Hall P Becker MB Affrime DL Cutler B Haehner-Daniels 2000 In vivo effects of interleukin-10 on human cytochrome P450 activity Clin Pharmacol Ther 67 32 43 10668851 10.1067/mcp.2000.103860 1:CAS:528:DC%2BD3cXhtV2rtr8%3D (Pubitemid 30078385)
13. M Islam RF Frye TJ Richards I Sbeitan SS Donelly P Glue, et al. 2002 Differential effect of IFNα-2b on the cytochrome P450 enzyme system: A potential basis of IFN toxicity and its modulation by other drugs Clin Cancer Res 8 2480 2487 12171873 1:CAS:528:DC%2BD38XmvVaiurY%3D (Pubitemid 34856329)
14. JA Sunman RL Hawke EL LeCluyse AD Kashuba 2004 Kupffer cell-mediated IL-2 suppression of CYP3A activity in human hepatocytes Drug Metab Dispos 32 359 363 14977871 10.1124/dmd.32.3.359 1:CAS:528:DC%2BD2cXhslOksLo%3D (Pubitemid 38263895)
15. ML Vee V Lecureur B Stieger O Fardel 2008 Regulation of drug transporter expression in human hepatocytes exposed to the proinflammatory cytokines tumor necrosis factor-α or interleukin-6 Drug Metab Dispos 37 685 693 19074973 10.1124/dmd.108.023630
16. A Aitken TA Richardson ET Morgan 2006 Regulation of drug-metabolizing enzymes and transporters in inflammation Annu Rev Pharmacol Toxicol 46 123 149 16402901 10.1146/annurev.pharmtox.46.120604.141059 1:CAS:528: DC%2BD28XisFKltLk%3D (Pubitemid 43271186)
17. F Vincenti R Mendez M Pescovitz PR Rajagopalan AH Wilkinson K Butt, et al. 2007 A phase I/II randomized open-label multicenter trial of efalizumab, a humanized anti-CD11a, anti-LFA-1 in renal transplantation Am J Transplant 7 1770 1777 17564637 10.1111/j.1600-6143.2007.01845.x 1:CAS:528:DC%2BD2sXotV2ntL0%3D (Pubitemid 46905435)
18. MC Genovese S Cohen L Moreland D Lium S Robbins R Newmark, et al. 2004 Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate Arthritis Rheum 50 5 1412 1419 15146410 10.1002/art.20221 1:CAS:528: DC%2BD2cXkvFykurw%3D (Pubitemid 38608062)
19. RS Herbst DH Johnson E Mininberg DP Carbone T Henderson ES Kim, et al. 2005 Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer J Clin Oncol 23 11 2544 2555 15753462 10.1200/JCO.2005.02.477 1:CAS:528:DC%2BD2MXjvVyktLY%3D
20. MD Pegram D Chan RA Dickmann 2006 Phase II combined biological therapy targeting the HER2 proto-oncogene and vascular endothelial growth factor using trastuzumab (T) and bevacizumab (B) as first line therapy of HER2 amplified breast cancer [abstract 301] Breast Cancer Res Treat 100 suppl 1 S28
21. KN Ganjoo CS An MJ Robertson LI Gordon JA Sen J Weisenbach, et al. 2006 Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: safety, biomarker and pharmacokinetic analysis Leuk Lymphoma 47 6 998 1005 16840188 10.1080/10428190600563821 1:CAS:528:DC%2BD28XpvVGru7o%3D (Pubitemid 44102960)
22. S Wijngaarden JA van Roon JG van de Winkel JW Bijlsma FP Lafeber 2005 Down-regulation of activating Fcgamma receptors on monocytes of patients with rheumatoid arthritis upon methotrexate treatment Rheumatology (Oxford) 44 6 729 734 10.1093/rheumatology/keh583 1:CAS:528:DC%2BD2MXktl2qtL0%3D (Pubitemid 41487200)
23. RN Maini FC Breedveld JR Kalden JS Smolen D Davis JD Macfarlane, et al. 1998 Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis Arthritis Rheum 41 9 1552 1563 9751087 10.1002/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W 1:CAS:528:DyaK1cXmsVChtbg%3D (Pubitemid 28459913)
24. Humira® (Adalimumab) [packet insert]. Chicago, IL. Abbott Laboratories; 2010.
25. N Emi Aikawa JF de Carvalho C Artur Almeida Silva E Bonfá 2010 Immunogenicity of anti-TNF-α agents in autoimmune diseases Clin Rev Allergy Immunol 38 82 89 19565360 10.1007/s12016-009-8140-3 1:CAS:528: DC%2BC3cXktVCgurY%3D
26. EM Vasquez R Pollak 1997 OKT3 therapy increases cyclosporine blood levels Clin Transplant 11 1 38 41 9067693 1:STN:280:DyaK2s3itVGgsw%3D%3D (Pubitemid 27107708)
27. NM Sifontis E Benedetti EM Vasquez 2002 Clinically significant drug interaction between basiliximab and tacrolimus in renal transplant recipients Transplant Proc 34 1730 1732 12176554 10.1016/S0041-1345(02)03000-2 1:CAS:528:DC%2BD38XmtlKhsr4%3D
28. J Strehlau L Pape G Offner B Nashan JH Ehrich 2000 Interleukin-2 receptor antibody-induced alterations of ciclosporin dose requirements in paediatric transplant recipients Lancet 356 1327 1328 11073027 10.1016/S0140-6736(00)02822- 1 1:CAS:528:DC%2BD3cXotVOgt7o%3D
29. Arcalyst® (Rilonacept) [packet insert]. Tarrytown, NY. Regeneron Pharmaceuticals, Inc.; 2010.
30. Ilaris® (Canakinumab) [packet insert]. East Hanover, NJ. Novartis Pharmaceuticals Corporation; 2009.
31. Simponi® (Golimumab) [packet insert]. Horsham, PA. Centocor Ortho Biotech Inc.; 2010.
32. Stelara® (Ustekinumab) [packet insert]. Horsham, PA. Centocor Ortho Biotech Inc.; 2010.
33. Actemra® (Tocilizumab) [packet insert]. South San Francisco, CA. Genentech, Inc.; 2010.
34. CS Denlinger R Blanchard L Xu C Bernaards S Litwin C Spittle, et al. 2009 Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors Cancer Chemother Pharmacol 65 1 97 105 19415281 10.1007/s00280-009-1008-7 1:CAS:528:DC%2BD1MXhtFegu77P
35. European Medicine Agency. Clinical efficacy and safety guidelines introduction. London, UK. http://www.emea.europa.eu/htms/human/humanguidelines/ efficacy.htm. Accessed 04 Jan 2011.
36. S-M Huang R Temple 2008 Is this the drug or dose for you?-Impact of ethnic factors in global drug development, regulatory review and clinical practice Clin Pharmacol Ther 84 3 287 294 18714314 10.1038/clpt.2008.144
37. US Food and Drug Administration. Clinical Pharmacology Guidance for Industry. Rockville, MD. http://www.fda.gov/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm064982.htm. Accessed July 5, 2010.
38. KM Giacomini S-M Huang DJ Tweedie LZ Benet KLR Brouwer X Chu A Dahlin R Evers V Fischer KM Hillgren KA Hoffmaster T Ishikawa D Keppler RB Kim CA Lee M Niemi JW Polli Y Sugiyama PW Swaan JA Ware SH Wright SW Yee MJ Zamek-Gliszczynski L Zhang 2010 The International Transporter Consortium, ITC. Membrane Transporters in Drug Development Nat Rev Drug Discov 9 215 236 20190787 10.1038/nrd3028 1:CAS:528:DC%2BC3cXisFelu74%3D
39. US Food and Drug Administration. Briefing Information for the March 17, 2010 Meeting of the Pharmaceutical Science and Clinical Pharmacology Advisory Committee. Rockville, MD. 2010. http://www.fda.gov/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/ AdvisoryCommitteeforPharmaceuticalScienceandClinicalPharmacology/ucm204260.htm. Accessed 5 July 2010.
40. P Zhao L Zhang J Grillo Q Liu JM Bullock YJ Moon P Song S Brar R Madabushi TC Wu BP Booth NA Rahman K Reynolds E Gil Berglund LJ Lesko S-M Huang 2011 Application of physiologically based pharmacokinetic (PBPK) modeling and simulation in regulatory review Clin Pharmacol Ther 89 2 259 267 21191381 10.1038/clpt.2010.298 1:STN:280:DC%2BC3M7ivFKisw%3D%3D
41. S-M Huang J Woodcock 2010 Commentary on ITC Membrane Transporters in Drug Development; Report from the FDA Critical Path Initiative Sponsored Workshop Nat Rev Drug Discov 9 175 176 20222180 10.1038/nrd3124 1:CAS:528: DC%2BC3cXisFelu7o%3D
42. Remicade® (Infliximab) [packet insert]. Horsham, PA. Centocor Ortho Biotech Inc.; 2010.